Related Experiment Videos
Lymphoma in a black patient with actinic reticuloid treated with PUVA: possible etiologic considerations
R Ashinoff1, M R Buchness, H W Lim
1Dermatology Service, New York Veterans Administration Medical Center, New York, NY 10010.
Abstract:
A 47-year-old black man with a chronic photocontact dermatitis that evolved into actinic reticuloid was treated with systemically administered PUVA for 15 months. Subsequently an isolated nodule of non-mycosis fungoides T cell lymphoma developed. The use of PUVA may have predisposed this patient to the development of a frank malignancy.
Insights
Photochemotherapy (PUVA) treatment for actinic reticuloid may increase the risk of developing T cell lymphoma. This case study highlights a potential link between PUVA and malignancy in patients with chronic skin conditions.
Area of Science:
- Dermatology
- Oncology
- Photobiology
Background:
- Chronic photocontact dermatitis can progress to actinic reticuloid, a condition characterized by photosensitivity and eczematous lesions.
- Actinic reticuloid is a rare, severe form of chronic actinic dermatitis, often associated with significant light sensitivity.
Observation:
- A 47-year-old male patient with chronic photocontact dermatitis, which evolved into actinic reticuloid, underwent 15 months of systemic photochemotherapy (PUVA).
- Following PUVA treatment, the patient developed an isolated nodule identified as non-mycosis fungoides T cell lymphoma.
Findings:
- The development of T cell lymphoma subsequent to PUVA therapy suggests a potential carcinogenic effect.
- This case indicates a possible association between long-term PUVA exposure and the onset of cutaneous T cell lymphoma.
Implications:
- The findings warrant further investigation into the oncogenic risks associated with PUVA therapy in patients with chronic photodermatoses.
- Clinicians should consider the potential for malignancy when managing patients with actinic reticuloid treated with PUVA.
- This case underscores the importance of long-term monitoring for secondary malignancies in patients undergoing photochemotherapy.